Skip to main content

Research Repository

See what's under the surface

Advanced Search

Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery

Breen, Alastair F.; Scurr, David; Cassioli, Maria Letizia; Wells, Geoffrey; Thomas, Neil R.; Zhang, Jihong; Turyanska, Lyudmila; Bradshaw, Tracey D.

Authors

Alastair F. Breen

David Scurr

Maria Letizia Cassioli

Geoffrey Wells

Neil R. Thomas

Jihong Zhang

Lyudmila Turyanska

Tracey D. Bradshaw



Abstract

Introduction: Advancment of novel anticancer drugs into clinic is frequently halted by their lack of solubility, reduced stability under physiological conditions, and non-specific uptake by normal tissues, causing systemic toxicity. Their progress to clinic could be accelerated by development of new formulations employing suitable and complementary drug delivery vehicles.

Methods: A robust method for apoferritin (AFt)-encapsulation of antitumour benzothiazoles has been developed for enhanced activity against and drug delivery to benzothiazole-sensitive cancers.

Results: More than 70 molecules of benzothiazole 5F 203 were encapsulated per AFt cage. Post-encapsulation, the size and integrity of the protein cages were retained as evidenced by dynamic light scattering. ToF-SIMS depth profiling using an argon cluster beam confirmed 5F 203 exclusively within the AFt cavity. Improved encapsulation of benzothiazole lysyl-amide prodrugs was achieved (~130 molecules of Phortress per AFt cage). Transferrin receptor 1, TfR1, was detected in lysates prepared from most cancer cell lines studied, contributing to enhanced anticancer potency of the AFt-encapsulated benzothiazoles (5F 203, Phortress, GW 610, GW 608-Lys). Nanomolar activity was demonstrated by AFt-formulations in breast, ovarian, renal and gastric carcinoma cell lines, whereas GI50 >50 µM was observed in non-tumourigenic MRC-5 fibroblasts. Intracellular 5F 203, a potent arylhydrocarbon receptor (AhR) ligand, and inducible expression of cytochrome P450 (CYP) 1A1 were detected following exposure of sensitive cells to AFt-5F 203, confirming that the activity of benzothiazoles was not compromised following encapsulation.

Conclusions: Our results show enhanced potency and selectivity of AFt-encapsulated 5F 203 against carcinomas derived from breast, ovarian, renal, colorectal as well as gastric cancer models, and offer realistic prospects for potential refinement of tumour-targeting and treatment, and merit further in vivo investigations.

Journal Article Type Article
Publication Date Dec 5, 2019
Print ISSN 1176-9114
Electronic ISSN 1178-2013
Publisher Dove Medical Press
Peer Reviewed Peer Reviewed
Volume 14
Pages 9525-9534
APA6 Citation Breen, A. F., Scurr, D., Cassioli, M. L., Wells, G., Thomas, N. R., Zhang, J., …Bradshaw, T. D. (2019). Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery. International Journal of Nanomedicine, 14, 9525-9534. https://doi.org/10.2147/IJN.S226293
DOI https://doi.org/10.2147/IJN.S226293
Keywords Benzothiazole, Apoferritin, Transferrin receptor, Anticancer activity, Drug delivery
Publisher URL https://www.dovepress.com/protein-encapsulation-of-experimental-anticancer-agents-5f-203-and-pho-peer-reviewed-article-IJN

Files

Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery (3.3 Mb)
PDF





You might also like



Downloadable Citations

;